Pharmaceutical

AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Jul 6, 2024 - 04:00
AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Read the original article

Tags:

Previous Article

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval

Next Article

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MA...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Truvian presents data for its desktop blood-testing device in a field still in Theranos’s shadow

STAT+: Truvian presents data for its desktop blood-test...

Jul 26, 2023

FDA approves Pfizer’s RSV vaccine designed to protect newborns by immunizing parent

FDA approves Pfizer’s RSV vaccine designed to protect n...

Aug 21, 2023

The challenges of clinical data management: Can consent management software help?

The challenges of clinical data management: Can consent...

Jun 9, 2023